Article
Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status.
Drug metabolism and disposition: the biological fate of chemicals - 1 Oct 2001
Kosuge K, Jun Y, Watanabe H, Kimura M, Nishimoto M, Ishizaki T, Ohashi K
Abstract excerpt
Diazepam is metabolized by CYP2C19 and CYP3A4 in the liver. CYP2C19 shows genetic polymorphism associated with the poor metabolizer (PM) and extensive metabolizer (EM) phenotypes. The aim of this study was to assess the effect of diltiazem, a CYP3A4 inhibitor, on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Thirteen healthy volunteers (eight EMs and five PMs) were given...
Topics
- Adult
- Antihypertensive Agents
- Aryl Hydrocarbon Hydroxylases
- Cross-Over Studies
- Cytochrome P-450 CYP2C19
- Cytochrome P-450 CYP3A
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme System
- Diazepam
- Diltiazem
- Drug Interactions
- Genotype